NASDAQ:BRNS | Free Cash Flow | Barinthus Biotherapeutics plc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2020-03-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$3.37M$0.00-$3.37M
2025-12-31-$4.24M$0.00-$4.24M
2025-03-31-$14.9M$5,000.00-$14.91M
2024-12-31$13.09M$278,000.00$12.81M
2024-03-31-$11.82M$308,000.00-$12.13M
2023-12-31-$19.6M-$153,000.00-$19.76M
2023-03-31-$3.17M$2.51M-$5.68M
2022-12-31-$11.34M$586,000.00-$11.93M
2022-03-31-$6.58M$1.09M-$7.67M-295.49%
2021-12-31-$7.97M$424,000.00-$8.4M
2021-03-31-$7.97M$392,000.00-$8.36M
2020-12-31-$4.9M$195,000.00-$5.09M
2020-03-31-$4.32M$22,000.00-$4.34M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$47.98M$37,000.00-$48.02M
2024-12-31-$28.94M$892,000.00-$29.83M
2023-12-31-$50.93M$5.41M-$56.34M
2022-12-31-$14.43M$6.14M-$20.57M-385.04%
2021-12-31-$32.58M$1.15M-$33.73M
2020-12-31-$11.03M$293,000.00-$11.32M